The newly published report titled “Global Gene Therapy for Blood Disorders Market– By Trends, Industry Competition Analysis, Pipeline Analysis/Clinical Trial, Revenue (US$ Billions) and Forecast Till 2034.” features in-depth analysis and an extensive market study, exploring its significant upcoming years industry factors.
According to the latest gene therapy industry market research report, the global Therapy for Blood Disorders Market Size is estimated to grow at a 15.3% CAGR during the forecast period for 2025-2034.
Request For Free Sample Report:
https://www.insightaceanalytic.com/request-sample/1156
Human genomes are modified through genetic therapy for the treatment of disease. It has excellent potential for treating rare blood diseases like sickle cell anaemia and haemophilia. CRISPR-Cas9, a gene-editing technique, is being adopted as a weapon against rare diseases by many biopharmaceutical corporations. CRISPR Therapeutics and Vertex Pharmaceuticals are conducting a phase I / II trial of CTX001, a CRISPR / Cas9-based genetic therapy, to treat sickle cell disease. In the coming years, the increasing prevalence of genetic and blood disorders, high demand for personalized medicine, increased healthcare expenditures, and increased R&D activities to develop promising genetic therapies for haematology are anticipated to drive the market. According to a study published in the PLOS Medicine Journal, the global incidence of sickle cell anaemia is expected to increase by approximately 30 per cent by 2050. Consequently, the increase in rare haematology disorders is a significant market driver.
Nevertheless, the high cost of gene therapy treatment and the potential adverse effects of the therapies are anticipated to impede the market penetration of gene therapy treatment over the forecast period.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1156
The prominent players in the gene therapy for blood disorders industry include:
BioMarin Pharmaceutical Inc. (U.S.), Medgenics (U.S.), Spark Therapeutics (U.S.), bluebird bio, Inc. (U.S.), Shire (U.S.), CRISPR Therapeutics (U.S.), Freeline Therapeutics (U.K.), OrphageniX (U.S.), Errant Gene Therapeutics (U.S.), Sangamo Therapeutics (U.S.), Sigilon Therapeutics, Inc. (U.S.), uniQure (Netherlands), Angiocrine Bioscience (U.S.), and Sanofi Genzyme (U.S.), and other prominent players.
Gene Therapy for Blood Disorders Market Regional Analysis:
North America is predicted to account for the largest share of the gene therapy for blood disorders market during the forecast years, followed by Europe, owing to the rising prevalence of various blood disorders, well-developed healthcare systems, and increasing R&D investments to develop effective gene therapies to treat rare diseases. According to the Hemophilia Federation of America, Hemophilia affects 1 in 5,000 male births, and around 400 babies are born with hemophilia in the U.S annually. Worldwide 400,000 individuals are living with hemophilia, and approximately 20,000 people are living with it in the United States alone.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1156
The Global Gene Therapy for Blood Disorders Market Segments
The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2025 to 2034 based on Indication
- Sickle Cell Anemia
- β-thalassemia
- Hemophilia B
- Hemophilia A
- Other Indication
The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2025 to 2034 based on Mechanism of Action
- Gene Therapy
- Gene Editing
The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2025 to 2034 based on Region
- Europe
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
North America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2025 to 2034
- U.S.
- Canada
Europe Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2025 to 2034
- Germany
- Spain
- France
- Russia
- Italy
- Rest of Europe
Asia Pacific Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2025 to 2034
- India
- Japan
- China
- Australia & New Zealand
- South Korea
Latin America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2025 to 2034
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2025 to 2034
- South Africa
- GCC Countries
- Rest of the Middle East & Africa
Get More Information :@
https://www.insightaceanalytic.com/report/global-gene-therapy-for-blood-disorders-market/1156
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
